Ready or Not: Responding to Measles in the Postelimination Era

Julia Shaklee Sammons, MD, MSCE

Although endemic measles was eliminated in the United States in 2000 (1), 2 concurrent measles outbreaks at opposite ends of the country offer a sobering reminder of the threat of this global disease. As more parents decline to vaccinate their children, measles incidence is increasing—a fact that alarms me both as a hospital epidemiologist and as a parent of a vulnerable infant too young to receive the measles vaccine. Because infected patients are likely to seek medical care, hospitals and clinics may inadvertently fuel transmission if patients with measles are not rapidly triaged and isolated. Yet, because of the success of the measles vaccine, many clinicians have never seen measles and may not be able to recognize its features. It is crucial that providers become familiar with this deadly disease and apply the necessary control measures to contain it.

An estimated 20 million cases of measles occur each year worldwide (2). In the prevaccine era, approximately 500,000 measles cases occurred in the United States annually, with 500 deaths and 48,000 hospitalizations (1). After elimination, the median annual number of cases decreased to 60, but this number is steadily increasing. Since 2010, there has been an average of 155 cases per year (2, 3). In 2014, there has been 106 measles cases reported in the first 3 months alone (3).

High vaccination coverage is essential to prevent spread after importation. However, coverage with measles, mumps, and rubella (MMR) vaccine varies by state. The recent outbreaks in New York City and Orange County, California, remind us how quickly imported cases of measles can spread in communities with large numbers of unvaccinated persons. Although vaccination coverage among children aged 19 to 35 months continues to be near or above 90% nationwide, 15 states had MMR vaccination rates below 90% according to the National Immunization Survey (4). States allowing philosophical exemptions from vaccination have significantly higher rates of unvaccinated children (5). In addition, unvaccinated children are likely to cluster geographically, thus increasing the risk for outbreaks after importation (5). In fact, most postelimination measles cases have been due to outbreaks. In 2013, 75% of cases in the first 8 months of the year were due to 8 outbreaks (2). Most occurred in unvaccinated persons (82%) or those with unknown vaccination status (9%) (2). As expected, 99% of cases could be linked to an imported case that led to a community-based outbreak. Of the imported measles cases, 50% were from Europe (2).

Measles is one of the most contagious infectious diseases known, with secondary attack rates greater than 90% in susceptible contacts (6). Transmission occurs primarily through direct contact with infectious droplets; however, measles virus can survive for up to 2 hours in fine particle aerosols and be transmitted via inhalation of small droplets even without face-to-face contact (6). The incubation period ranges from 7 to 21 days but is generally 8 to 12 days from exposure to symptom onset. Persons with measles are contagious from 4 days before to 4 days after appearance of rash, underscoring the importance of early recognition for returned travelers with relevant symptoms even before the rash appears (7).

It is essential that providers maintain a high level of suspicion for measles in persons with febrile rash illness who have recently traveled or have had contact with travelers and are able to recognize its clinical features (8). Measles is characterized by a prodrome of fever (up to 40.6 °C), cough, coryza, and conjunctivitis. A characteristic red, blotchy, “morbilliform” rash appears 2 to 4 days after symptom onset (Figure 1); it typically begins on the face before spreading downward and becoming confluent (8). Pathognomonic Koplik spots appear 1 to 2 days before the rash and last 2 to 3 days; they are small, slightly raised, bluish-white spots on an erythematous base and have been reported in 60% to 70% of patients with measles, although they are probably present in all cases (Figure 2) (7, 9).

Measles rash may be confused with other viral exanthems (erythema infectiosum [fifth disease] or roseola), Kawasaki disease, or scarlet fever. Immunocompromised patients may not develop a characteristic rash (7). Complications are common in young children and include diarrhea, otitis media, bronchopneumonia, and croup; acute encephalitis.

This article was published online first at www.annals.org on 29 April 2014.
Waiting room, use of a surgical mask and distancing the immediately available and the patient must remain in a proper isolation. If an examination room is not immediately available, the patient should be placed in a private room with the door closed (10). A surgical mask can be worn by the patient to limit spread. If an airborne infection isolation room is un- available, the patient should be placed in a negative-air-pressure isolation room, or airborne-infection isolation room. These rooms are equipped with special air handling and ventilation systems that contain and safely remove infectious particles (10). Airborne precautions should be continued for 4 days after rash onset in healthy persons or for the duration of illness in immunocompromised patients; for those not requiring hospitalization, voluntary quarantine is advised.

As measles incidence increases, clinicians have a vital role to play. We need to talk to our patients about measles vaccination and remind them what is at stake if imported measles cases continue to land in communities of unvaccinated persons, especially for those who are too young or ineligible to be vaccinated. Meanwhile, we must ensure that our facilities do not become centers for secondary measles transmission—prompt recognition of suspected cases and rapid implementation of control measures are critical to prevent further spread.

From Perelman School of Medicine, University of Pennsylvania, and Division of Infectious Diseases and Department of Infection Prevention and Control, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania.

Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-0892.

Requests for Single Reprints: Julia Shaklee Sammons, MD, MSCE, The Children’s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Main Building, A-Level, Room AE22, Philadelphia, PA 19104; e-mail, sammonsj@email.chop.edu.

Author contributions are available at www.annals.org.


References
Author Contributions: Conception and design: J.S. Sammons.
Analysis and interpretation of the data: J.S. Sammons.
Drafting of the article: J.S. Sammons.
Final approval of the article: J.S. Sammons.
Collection and assembly of data: J.S. Sammons.